Plasma VEGF and IL-8 levels in patients with mixed dyslipidaemia. Effect of rosuvastatin monotherapy or its combination at a lower dose with omega-3 fatty acids: A pilot study.

CONCLUSIONS: We show for the first time that either rosuvastatin monotherapy or its combination at a lower dose with ω-3 PUFAs reduces IL-8 levels in mixed dyslipidaemic patients. High-dose rosuvastatin monotherapy reduces VEGF values, whereas a significant increase is observed in patients receiving lower dose rosuvastatin with ω-3 PUFAs. The clinical significance of the above findings regarding cardiovascular risk remains to be established. PMID: 27041244 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27041244?dopt=Abstract

Source: Current Vascular Pharmacology - April 3, 2016 Category: Drugs & Pharmacology Authors: Chantzichristos VG, Agouridis AP, Moutzouri E, Stellos K, Elisaf MS, Tselepis AD Tags: Curr Vasc Pharmacol Source Type: research